Next Article in Journal
Distinct Outcomes of Oropharyngeal Squamous Cell Carcinoma Patients after Distant Failure According to p16 Status: Implication in Therapeutic Options
Previous Article in Journal
Prognostic Impact of APOBEC3B Expression in Metastatic Urothelial Carcinoma and Its Association with Tumor-Infiltrating Cytotoxic T Cells
Open AccessArticle

Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer

1
Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
2
Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(3), 1663-1672; https://doi.org/10.3390/curroncol28030155
Received: 18 March 2021 / Revised: 20 April 2021 / Accepted: 26 April 2021 / Published: 29 April 2021
(This article belongs to the Section Genitourinary Oncology)
(1) This study investigated the prognostic impact of tumor size in patients with metastatic cervical cancer. (2) Methods: Seventy-three cervical cancer patients in our institute were stratified into two groups based on distant metastasis: para-aortic lymph node metastasis alone (IIIC2) or spread to distant visceral organs with or without para-aortic lymph node metastasis (IVB) to identify primary tumor size and concurrent chemoradiotherapy. (3) Results: The overall survival (OS) for patients with a tumor >6.9 cm in size was significantly poorer than that for patients with a tumor ≤6.9 cm in the IVB group (p = 0.0028); the corresponding five-year OS rates in patients with a tumor ≤6.9 and >6.9 cm were 53.3% and 13.4%, respectively. In the multivariate analysis, tumor size and primary treatment were significantly associated with survival in metastatic cervical cancer. (4) Conclusions: Tumor size ≤6.9 cm and concurrent chemoradiotherapy as the primary treatment were favorable prognostic factors for patients with metastatic cervical cancer. View Full-Text
Keywords: metastatic cervical cancer; tumor size; concurrent chemoradiotherapy; biomarker; prognosis metastatic cervical cancer; tumor size; concurrent chemoradiotherapy; biomarker; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Hattori, S.; Yoshikawa, N.; Mogi, K.; Yoshida, K.; Yoshihara, M.; Tamauchi, S.; Ikeda, Y.; Yokoi, A.; Nishino, K.; Niimi, K.; Suzuki, S.; Kajiyama, H. Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer. Curr. Oncol. 2021, 28, 1663-1672. https://doi.org/10.3390/curroncol28030155

AMA Style

Hattori S, Yoshikawa N, Mogi K, Yoshida K, Yoshihara M, Tamauchi S, Ikeda Y, Yokoi A, Nishino K, Niimi K, Suzuki S, Kajiyama H. Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer. Current Oncology. 2021; 28(3):1663-1672. https://doi.org/10.3390/curroncol28030155

Chicago/Turabian Style

Hattori, Satomi; Yoshikawa, Nobuhisa; Mogi, Kazumasa; Yoshida, Kosuke; Yoshihara, Masato; Tamauchi, Satoshi; Ikeda, Yoshiki; Yokoi, Akira; Nishino, Kimihiro; Niimi, Kaoru; Suzuki, Shiro; Kajiyama, Hiroaki. 2021. "Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer" Curr. Oncol. 28, no. 3: 1663-1672. https://doi.org/10.3390/curroncol28030155

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop